Short Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Rises By ∞

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 6,262 shares, a growth of ∞ from the July 30th total of 0 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 18,400 shares, the days-to-cover ratio is currently 0.3 days.

Appili Therapeutics Stock Performance

OTCMKTS:APLIF remained flat at $0.01 during mid-day trading on Friday. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.03. The stock has a market capitalization of $1.20 million, a price-to-earnings ratio of -0.23 and a beta of -0.04. The business has a 50 day simple moving average of $0.01 and a two-hundred day simple moving average of $0.01.

Appili Therapeutics (OTCMKTS:APLIF) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Appili Therapeutics Company Profile

Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.

Appili’s product pipeline features multiple candidates in various stages of development.